Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Effectiveness of COVID-19 vaccines administered in the 2023 autumnal campaigns in Europe: Results from the VEBIS primary care test-negative design study, September 2023–January 2024

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Contributors:
      EpiConcept Paris; Instituto Nacional de Saùde Dr Ricardo Jorge Portugal (INSA); Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública = Consortium for Biomedical Research of Epidemiology and Public Health (CIBERESP); Institute of Health Carlos III; Robert Koch Institute Berlin (RKI); Health Protection Surveillance Centre Dublin, Ireland (HPSC); Semmelweis University Budapest; Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP); Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU); Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA); Universidad Pública de Navarra Espagne = Public University of Navarra (UPNA)-Universidad de Navarra Pamplona (UNAV)-Clínica Universidad de Navarra Pamplona; National Institute for Public Health and the Environment Bilthoven (RIVM); Croatian Institute of Public Health Zagreb (CIPH); Public Health Agency of Sweden; Cantacuzino National Medico-Military Institute for Research Development = Institutul Național de Cercetare Dezvoltare Medico-Militară "Cantacuzino" Bucharest, Romania; University College Dublin Dublin (UCD); Infection et inflammation (2I); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM); Centre National de Référence des virus respiratoires (dont la grippe et le SARS-CoV2) Paris (CNR - laboratoire associé); Institut Pasteur Paris (IP)-Université Paris Cité (UPCité); Université Paris-Saclay; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP); Netherlands Institute for Health Services Research Utrecht (NIVEL); Consejeria de sanidad y servicios sociales Ceuta, Spain; European Centre for Disease Prevention and Control Solna, Sweden (ECDC); This study has received funding from the European Centre for Disease Prevention and Control under framework contract ECDC/2021/019.
    • Publication Information:
      CCSD
      Elsevier
    • Publication Date:
      2024
    • Collection:
      Institut Pasteur: HAL
    • Abstract:
      International audience ; In autumn 2023, European vaccination campaigns predominantly administered XBB.1.5 vaccine. In a European multicentre study, we estimated 2023 COVID-19 vaccine effectiveness (VE) against laboratory-confirmed symptomatic infection at primary care level between September 2023 and January 2024. Using a test-negative case–control design, we estimated VE in the target group for COVID-19 vaccination overall and by time since vaccination. We included 1057 cases and 4397 controls. Vaccine effectiveness was 40 % (95 % CI: 26–53 %) overall, 48 % (95 % CI: 31–61 %) among those vaccinated < 6 weeks of onset and 29 % (95 % CI: 3–49 %) at 6–14 weeks. Our results suggest that COVID-19 vaccines administered to target groups during the autumn 2023 campaigns showed clinically significant effectiveness against laboratory-confirmed, medically attended symptomatic SARS-CoV-2 infection in the 3 months following vaccination. A longer study period will allow for further variant-specific COVID-19 VE estimates, better understanding decline in VE and informing booster administration policies.
    • Relation:
      info:eu-repo/semantics/altIdentifier/pmid/38839521; PUBMED: 38839521; PUBMEDCENTRAL: PMC11252666
    • Accession Number:
      10.1016/j.vaccine.2024.05.067
    • Online Access:
      https://hal.science/hal-04608441
      https://hal.science/hal-04608441v1/document
      https://hal.science/hal-04608441v1/file/1-s2.0-S0264410X24006443-main.pdf
      https://doi.org/10.1016/j.vaccine.2024.05.067
    • Rights:
      http://creativecommons.org/licenses/by-nc-nd/ ; info:eu-repo/semantics/OpenAccess
    • Accession Number:
      edsbas.BE7177AA